文献速递临床试验与 GCP流行病学与生物统计

利用医疗系统数据作为临床试验结局:设计阶段需考虑的问题

Using healthcare systems data for outcomes in clinical trials: issues to consider at the design stage.
PubMed 文献 · Trials · 2024-01-29

PRIMORANT研究通过工作坊、咨询和讨论工作坊三阶段,在英国背景下识别临床试验设计阶段使用医疗系统数据(HSD)作为结局数据前需考虑的问题。咨询中78名受访者(95%)认为为试验者制定指南是可行的,最终围绕术语、可行性、内部试点、数据共享和数据归档五个领域形成指南。

要点

  • 临床试验设计阶段使用HSD前需考虑结局数据有效性、数据获取及时性、内部试点、数据共享、实际问题与决策。
  • 78名咨询受访者中95%认为制定试验者指南可行。
  • 指南覆盖术语、可行性、内部试点、后续数据共享和数据归档五个领域。

核心结论

  • 提供指南以帮助决定是否使用HSD作为结局数据,并协助试验者与登记处及其他HSD提供者合作改进试验设计与实施。

研究设计与样本

  • PRIMORANT研究分三阶段:初始工作坊界定试验者考虑使用HSD作为试验结局时面临的问题;随后对临床试验单位(CTU) staff、试验者、方法学家、临床医生、资助评审组和数据提供者开展咨询;最后举行讨论工作坊反馈咨询结果、展示案例研究并分组讨论问题。

主要发现

  • 咨询过程涉及的关键主题包括结局数据有效性、数据获取及时性、内部试点、数据共享、实际问题和决策。
  • 78名咨询受访者中95%认为制定试验者指南可行。

关键数值与推荐

  • 讨论工作坊后制定的指南覆盖五个广泛领域:术语、可行性、内部试点、后续数据共享和数据归档。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Healthcare system data (HSD) are increasingly used in clinical trials, augmenting or replacing traditional methods of collecting outcome data. This study, PRIMORANT, set out to identify, in the UK context, issues to be considered before the decision to use HSD for outcome data in a clinical trial is finalised, a methodological question prioritised by the clinical trials community. METHODS: The PRIMORANT study had three phases. First, an initial workshop was held to scope the issues faced by trialists when considering whether to use HSDs for trial outcomes. Second, a consultation exercise was undertaken with clinical trials unit (CTU) staff, trialists, methodologists, clinicians, funding panels and data providers. Third, a final discussion workshop was held, at which the results of the consultation were fed back, case studies presented, and issues considered in small breakout groups. RESULTS: Key topics included in the consultation process were the validity of outcome data, timeliness of data capture, internal pilots, data-sharing, practical issues, and decision-making. A majority of consultation respondents (n = 78, 95%) considered the development of guidance for trialists to be feasible. Guidance was developed following the discussion workshop, for the five broad areas of terminology, feasibility, internal pilots, onward data sharing, and data archiving. CONCLUSIONS: We provide guidance to inform decisions about whether or not to use HSDs for outcomes, and if so, to assist trialists in working with registries and other HSD providers to improve the design and delivery of trials.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Toader AM, Campbell MK, Quint JK, et al. Using healthcare systems data for outcomes in clinical trials: issues to consider at the design stage. Trials. 2024. PMID: 38287428. doi:10.1186/s13063-024-07926-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。